Search

Your search keyword '"Parikh, Chirag R"' showing total 517 results
Start Over Author "Parikh, Chirag R" Search Limiters Peer Reviewed
517 results on '"Parikh, Chirag R"'

4. Urine Biomarkers of Kidney Tubule Health and Risk of Incident CKD in Persons Without Diabetes: The ARIC, MESA, and REGARDS Studies

Author

Amatruda, Jonathan G., Katz, Ronit, Rebholz, Casey M., Sarnak, Mark J., Gutierrez, Orlando M., Schrauben, Sarah J., Greenberg, Jason H., Coresh, Josef, Cushman, Mary, Waikar, Sushrut, Parikh, Chirag R., Schelling, Jeffrey R., Jogalekar, Manasi P., Bonventre, Joseph V., Vasan, Ramachandran S., Kimmel, Paul L., Ix, Joachim H., and Shlipak, Michael G.

Published
2024
Full Text
View/download PDF

6. Corrigendum: Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis

Author

Moledina, Dennis G., Obeid, Wassim, Smith, Rex N., Rosales, Ivy, Sise, Meghan E., Moeckel, Gilbert, Kashgarian, Michael, Kuperman, Michael, Campbell, Kirk N., Lefferts, Sean, Meliambro, Kristin, Bitzer, Markus, Perazella, Mark A., Luciano, Randy L., Pober, Jordan S., Cantley, Lloyd G., Colvin, Robert B., Wilson, F. Perry, and Parikh, Chirag R.

Subjects
Proteins, Kidney diseases -- Diagnosis, Health care industry
Abstract

In the abstract and the legend for Figure 1, the descriptions of the Olink Proteomics assays utilized were incorrect. The correct descriptions appear below. The HTML and PDF versions of [...]

Published
2024
Full Text
View/download PDF

8. An atlas of healthy and injured cell states and niches in the human kidney

Author

Lake, Blue B., Menon, Rajasree, Winfree, Seth, Hu, Qiwen, Melo Ferreira, Ricardo, Kalhor, Kian, Barwinska, Daria, Otto, Edgar A., Ferkowicz, Michael, Diep, Dinh, Plongthongkum, Nongluk, Knoten, Amanda, Urata, Sarah, Mariani, Laura H., Naik, Abhijit S., Eddy, Sean, Zhang, Bo, Wu, Yan, Salamon, Diane, Williams, James C., Wang, Xin, Balderrama, Karol S., Hoover, Paul J., Murray, Evan, Marshall, Jamie L., Noel, Teia, Vijayan, Anitha, Hartman, Austin, Chen, Fei, Waikar, Sushrut S., Rosas, Sylvia E., Wilson, Francis P., Palevsky, Paul M., Kiryluk, Krzysztof, Sedor, John R., Toto, Robert D., Parikh, Chirag R., Kim, Eric H., Satija, Rahul, Greka, Anna, Macosko, Evan Z., Kharchenko, Peter V., Gaut, Joseph P., Hodgin, Jeffrey B., Eadon, Michael T., Dagher, Pierre C., El-Achkar, Tarek M., Zhang, Kun, Kretzler, Matthias, and Jain, Sanjay

Published
2023
Full Text
View/download PDF

12. A sub-study of the POISE-3 randomized trial examined effects of a perioperative hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of acute kidney injury

Author

Garg, Amit X., Marcucci, Maura, Cuerden, Meaghan S., Sontrop, Jessica M., Painter, Thomas W., Lomivorotov, Vladimir, Sessler, Daniel I., Chan, Matthew T.V., Borges, Flavia K., Leslie, Kate, Duceppe, Emmanuelle, Parikh, Chirag R., Roshanov, Pavel, Martínez-Zapata, María José, Wang, Chew Yin, Xavier, Denis, Efremov, Sergey, Landoni, Giovanni, Kleinlugtenbelt, Ydo V., Szczeklik, Wojciech, Schmartz, Denis, Meyhoff, Christian S., Short, Timothy G., Amir, Mohammed, Torres, David, Wittmann, Maria, Patel, Ameen, Ruetzler, Kurt, Parlow, Joel L., Jayaram, Raja, Polanczyk, Carisi A., Fleischmann, Edith, Tandon, Vikas, Astrakov, Sergey V., Conen, David, Kei Wu, William Ka, Cheong, Chao Chia, Ayad, Sabry, Kirov, Mikhail, de Nadal, Miriam, Likhvantsev, Valery V., Paniagua, Pilar, Aguado, Hector J., Ofori, Sandra N., Vincent, Jessica, Copland, Ingrid, Balasubramanian, Kumar, Biccard, Bruce M., Srinathan, Sadeesh, Ismoilov, Samandar, Wang, Michael Ke, Kurz, Andrea, Belley-Cote, Emilie P., Bhatt, Keyur, Eikelboom, John, Gross, Peter, Lamy, Andre, McGillion, Michael, McIntyre, William, Richards, Toby, Spence, Jessica, Van Helder, Thomas, Whitlock, Richard, and Devereaux, P.J.

Published
2024
Full Text
View/download PDF

15. The ASSESS-AKI Study found urinary epidermal growth factor is associated with reduced risk of major adverse kidney events

Author

Menez, Steven, Wen, Yumeng, Xu, Leyuan, Moledina, Dennis G., Thiessen-Philbrook, Heather, Hu, David, Obeid, Wassim, Bhatraju, Pavan K., Ikizler, T. Alp, Siew, Edward D., Chinchilli, Vernon M., Garg, Amit X., Go, Alan S., Liu, Kathleen D., Kaufman, James S., Kimmel, Paul L., Himmelfarb, Jonathan, Coca, Steven G., Cantley, Lloyd G., and Parikh, Chirag R.

Published
2023
Full Text
View/download PDF

16. Relationship between biomarkers of tubular injury and intrarenal hemodynamic dysfunction in youth with type 1 diabetes

Author

Johnson, Melissa J., Tommerdahl, Kalie L., Vinovskis, Carissa, Waikar, Sushrut, Reinicke, Trenton, Parikh, Chirag R., and Obeid, Wassim

Subjects
Diabetic nephropathies -- Diagnosis -- Risk factors -- Demographic aspects, Health
Abstract

Background Early identification of youth with type 1 diabetes (T1D) at risk for diabetic kidney disease may improve clinical outcomes. We examined the cross-sectional relationship between kidney biomarkers neutrophil gelatinase-associated lipocalin (NGAL), copeptin, interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1), chitinase-3-like protein-1 (YKL-40), and monocyte chemoattractant protein-1 (MCP-1) and intrarenal hemodynamic function in adolescents with T1D. Methods Urine albumin-to-creatinine ratio (UACR), renal vascular resistance (RVR), glomerular filtration rate (GFR), intraglomerular pressure (P.sub.GLO), efferent arteriole resistance (R.sub.E), afferent arteriolar resistance (R.sub.A), and renal plasma flow (RPF), and the above indicated biomarkers were assessed in youth aged 12-21 years with and without T1D of < 10 years duration. Results Fifty adolescents with T1D (16.1 ± 3.0 years, HbA1c 8.6 ± 1.2%) and 20 adolescents of comparable BMI without T1D (16.1 ± 2.9 years, HbA1c 5.2 ± 0.2%) were enrolled. Adolescents with T1D demonstrated significantly higher GFR, RPF, R.sub.E, and P.sub.GLO than controls (39%, 33%, 74%, and 29%, respectively, all p < 0.0001). Adolescents with T1D also exhibited significantly lower RVR and R.sub.A than controls (25% and 155%, respectively, both p < 0.0001). YKL-40 and KIM-1 concentrations, respectively, were positively associated with GFR (r: 0.43, p = 0.002; r: 0.41, p = 0.003), RPF (r: 0.29, p = 0.08; r: 0.34, p = 0.04), UACR (r: 0.33, p = 0.02; r: 0.50, p = 0.0002), and P.sub.GLO (r: 0.45, p = 0.006; r: 0.52, p = 0.001) in adolescents with T1D. Conclusions Higher concentrations of biomarkers YKL-40 and KIM-1 may help define the risk for intraglomerular hemodynamic dysfunction in youth with T1D. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information., Author(s): Melissa J. Johnson [sup.1] , Kalie L. Tommerdahl [sup.1] [sup.2] [sup.3] , Carissa Vinovskis [sup.1] , Sushrut Waikar [sup.4] , Trenton Reinicke [sup.1] , Chirag R. Parikh [sup.5] , [...]

Published
2022
Full Text
View/download PDF

19. Evaluation of Plasma Biomarkers to Predict Major Adverse Kidney Events in Hospitalized Patients With COVID-19

Author

Deng, Jie, Atta, Mo, Bagnasco, Serena M., Ko, Albert, Iwasaki, Akiko, Farhadian, Shelli, Nelson, Allison, Casanovas-Massana, Arnau, White, Elizabeth B., Schulz, Wade, Coppi, Andreas, Young, Patrick, Nunez, Angela, Shepard, Denise, Matos, Irene, Strong, Yvette, Anastasio, Kelly, Brower, Kristina, Kuang, Maxine, Chiorazzi, Michael, Bermejo, Santos, Vijayakumar, Pavithra, Geng, Bertie, Fournier, John, Minasyan, Maksym, Muenker, M. Catherine, Moore, Adam J., Nadkarni, Girish, Menez, Steven, Coca, Steven G., Moledina, Dennis G., Wen, Yumeng, Chan, Lili, Thiessen-Philbrook, Heather, Obeid, Wassim, Garibaldi, Brian T., Azeloglu, Evren U., Ugwuowo, Ugochukwu, Sperati, C. John, Arend, Lois J., Rosenberg, Avi Z., Kaushal, Madhurima, Jain, Sanjay, Wilson, F. Perry, and Parikh, Chirag R.

Published
2023
Full Text
View/download PDF

22. Plasma Biomarkers as Risk Factors for Incident CKD

Author

Sarnak, Mark J., Katz, Ronit, Ix, Joachim H., Kimmel, Paul L., Bonventre, Joseph V., Schelling, Jeffrey, Cushman, Mary, Vasan, Ramachandran S., Waikar, Sushrut S., Greenberg, Jason H., Parikh, Chirag R., Coca, Steven G., Sabbisetti, Venkata, Jogalekar, Manasi P., Rebholz, Casey, Zheng, Zihe, Gutierrez, Orlando M., and Shlipak, Michael G.

Published
2022
Full Text
View/download PDF

24. Aminoaciduria and metabolic dysregulation during diabetic ketoacidosis: Results from the diabetic kidney alarm (DKA) study

Author

Melena, Isabella, Piani, Federica, Tommerdahl, Kalie L., Severn, Cameron, Chung, Linh T., MacDonald, Alexis, Vinovskis, Carissa, Cherney, David, Pyle, Laura, Roncal-Jimenez, Carlos A., Lanaspa, Miguel A., Rewers, Arleta, van Raalte, Daniël H., Cara-Fuentes, Gabriel, Parikh, Chirag R., Nelson, Robert G., Pavkov, Meda E., Nadeau, Kristen J., Johnson, Richard J., and Bjornstad, Petter

Published
2022
Full Text
View/download PDF

29. Kidney Recovery and Death in Critically Ill Patients With COVID-19–Associated Acute Kidney Injury Treated With Dialysis: The STOP-COVID Cohort Study

Author

Gupta, Hsu, Faugno, Goyal, Raichoudhury, Tariq, Meyer, Sharma, Leaf, Kshirsagar, Walther, Carl P., Anumudu, Samaya J., Arunthamakun, Justin, Kopecky, Kathleen F., Milligan, Gregory P., McCullough, Peter A., Nguyen, Thuy-Duyen, Shaefi, Shahzad, Krajewski, Megan L., Shankar, Sidharth, Pannu, Ameeka, Valencia, Juan D., Bauer, Kenneth A., Waikar, Sushrut S., Kibbelaar, Zoe A., Athavale, Ambarish M., Hart, Peter, Upadhyay, Shristi, Vohra, Ishaan, Oyintayo, Ajiboye, Green, Adam, Rachoin, Jean-Sebastien, Schorr, Christa A., Shea, Lisa, Edmonston, Daniel L., Mosher, Christopher L., Shehata, Alexandre M., Cohen, Zaza, Allusson, Valerie, Bambrick-Santoyo, Gabriela, Bhatti, Noor ul aain, Mehta, Bijal, WilliamsSamantha K. Brenner, Aquino, Walters, Patricia, Go, Ronaldo C., Rose, Keith M., Hernán, Miguel A., Zhou, Amy M., Kim, Ethan C., Lisk, Rebecca, Chan, Lili, Mathews, Kusum S., Coca, Steven G., Altman, Deena R., Saha, Aparna, Soh, Howard, Wen, Huei Hsun, Bose, Sonali, Leven, Emily A., Wang, Jing G., Mosoyan, Gohar, Pattharanitima, Pattharawin, Gallagher, Emily J., Friedman, Allon N., Guirguis, John, Kapoor, Rajat, Meshberger, Christopher, Kelly, Katherine J., Parikh, Chirag R., Garibaldi, Brian T., Corona-Villalobos, Celia P., Wen, Yumeng, Menez, Steven, Malik, Rubab F., Cervantes, Carmen Elena, Gautam, Samir C., Mallappallil, Mary C., Ouyang, Jie, John, Sabu, Yap, Ernie, Melaku, Yohannes, Mohamed, Ibrahim, Bajracharya, Siddhartha, Puri, Isha, Thaxton, Mariah, Bhattacharya, Jyotsna, Wagner, John, Boudourakis, Leon, Nguyen, H. Bryant, Ahoubim, Afshin, Thomas, Leslie F., Sirganagari, Dheeraj Reddy, Guru, Pramod K., Kashani, Kianoush, Tehranian, Shahrzad, Zhou, Yan, Bergl, Paul A., Rodriguez, Jesus, Shah, Jatan A., Gupta, Mrigank S., Kumar, Princy N., Lazarous, Deepa G., Kassaye, Seble G., Melamed, Michal L., Johns. Ryan Mocerino, Tanya S., Prudhvi, Kalyan, Zhu, Denzel, Levy, Rebecca V., Azzi, Yorg, Fisher, Molly, Yunes, Milagros, Sedaliu, Kaltrina, Golestaneh, Ladan, Brogan, Maureen, Thakkar, Jyotsana, Kumar, Neelja, Ross, Michael J., Chang, Michael, Athreya, Akshay, Farag, Mohamed, Schenck, Edward J., Cho, Soo Jung, Plataki, Maria, Alvarez-Mulett, Sergio L., Gomez-Escobar, Luis G., Pan, Di, Lee, Stefi, Krishnan, Jamuna, Whalen, William, Charytan, David, Macina, Ashley, Srivastava, Anand, Leidner, Alexander S., Martinez, Carlos, Kruser, Jacqueline M., Wunderink, Richard G., Hodakowski, Alexander J., Velez, Juan Carlos Q., Price-Haywood, Eboni G., Matute-Trochez, Luis A., Hasty, Anna E., Mohamed, Muner M.B., Avasare, Rupali S., Zonies, David, Al-Samkari, Hanny, Leaf, Rebecca Karp, Rosovsky, Rachel, Sise, Meghan E., Newman, Erik T., Omar, Samah Abu, Pokharel, Kapil K., Sharma, Shreyak, Singh, Harkarandeep, Correa, Simon, Shaukat, Tanveer, Kamal, Omer, Wang, Wei, Lee, Meghan, Strohbehn, Ian A., Li, Jiahua, Mueller, Ariel L., Redfern, Roberta E., Cairl, Nicholas S., Naimy, Gabriel, Abu-Saif, Abeer, Hall, Danyell, Bickley, Laura, Rowan, Chris, Madhani-Lovely, Farah, Peev, Vasil, Reiser, Jochen, Byun, John J., Vissing, Andrew, Kapania, Esha M., Post, Zoe, Patel, Nilam P., Hermes, Joy-Marie, Sutherland, Anne K., Patrawalla, Amee, Finkel, Diana G., Danek, Barbara A., Arikapudi, Sowminya, Paer, Jeffrey M., Cangialosi, Peter, Liotta, Mark, Radbel, Jared, Puri, Sonika, Sunderram, Jag, Scharf, Matthew T., Ahmed, Ayesha, Berim, Ilya, Vatson, Jayanth S., Karp, George, Anand, Shuchi, Levitt, Joseph E., Garcia, Pablo, Boyle, Suzanne M., Song, Rui, Zhang, Jingjing, Woo, Sang Hoon, Deng, Xiaoying, Katz-Greenberg, Goni, Sharshir, Moh’d A., Rusnak, Vadym V., Bansal, Anip, Podoll, Amber S., Chonchol, Michel, Sharma, Sunita, Burnham, Ellen L., Rashidi, Arash, Hejal, Rana, Judd, Eric, Latta, Laura, Tolwani, Ashita, Albertson, Timothy E., Adams, Jason Y., Chang, Steven Y., Beutler, Rebecca M., Schulze, Carl E., Macedo, Etienne, RheeKa, Harin, thleen D. Liu, Jotwani, Vasantha K., Koyner, Jay L., Shah, Chintan V., Jaikaransingh, Vishal, Toth-Manikowski, Stephanie M., Joo, Min J., Lash, James P., Neyra, Javier A., Chaaban, Nourhan, Elias, Madona, Ahmad, Yahya, Dy, Rajany, Iardino, Alfredo, Au, Elizabeth H., Sosa, Marie Anne, Taldone, Sabrina, Contreras, Gabriel, De La Zerda, David, Gershengorn, Hayley B., Fornoni, Alessia, Hayek, Salim S., Blakely, Pennelope, Berlin, Hanna, Azam, Tariq U., Shadid, Husam, Pan, Michael, O’Hayer, Patrick, Meloche, Chelsea, Feroze, Rafey, Padalia, Kishan J., Leya, Jeff, Donnelly, John P., Admon, Andrew J., Flythe, Jennifer E., Tugman, Matthew J., Chang, Emily H., Brown, Brent R., Leonberg-Yoo, Amanda K., Spiardi, Ryan C., Miano, Todd A., Roche, Meaghan S., Vasquez, Charles R., Bansal, Amar D., Ernecoff, Natalie C., Kapoor, Sanjana, Verma, Siddharth, Chen, Huiwen, Kovesdy, Csaba P., Molnar, Miklos Z., Azhar, Ambreen, Hedayati, S. Susan, Nadamuni, Mridula V., Shastri, Shani, Willett, Duwayne L., Short, Samuel A.P., Renaghan, Amanda D., Enfield, Kyle B., Bhatraju, Pavan K., Malik, A. Bilal, Semler, Matthew W., Vijayan, Anitha, Joy, Christina Mariyam, Li, Tingting, Goldberg, Seth, Kao, Patricia F., Schumaker, Greg L., Christov, Marta, Griffiths, Jennifer, Gupta, Sanjeev, Kapoor, Aromma, Chugh, Savneek, Wilson, Perry, Arora, Tanima, Ugwuowo, Ugochukwu, Hsu, Caroline M., Gupta, Shruti, Tighiouart, Hocine, Goyal, Nitender, Faugno, Anthony J., Tariq, Asma, Raichoudhury, Ritesh, Sharma, Jill H., Meyer, Leah, Kshirsagar, Ravi K., Jose, Aju, Leaf, David E., and Weiner, Daniel E.

Published
2022
Full Text
View/download PDF

31. Sex Differences in Hypertension and Its Management Throughout Life.

Author

Wan-Jin Yeo, Abraham, Rahul, Surapaneni, Aditya L., Schlosser, Pascal, Ballew, Shoshana H., Ozkan, Bige, Flaherty, Carina M., Bing Yu, Bonventre, Joseph V., Parikh, Chirag R., Kimmel, Paul L., Vasan, Ramachandran S., Coresh, Josef, and Grams, Morgan E.

Abstract

BACKGROUND: The prevalence of hypertension and uncontrolled hypertension may differ by age and sex. METHODS: We included participants in the Atherosclerosis Risk in Communities study at seven study visits over 33 years (visit 1: 15 636 participants; mean age, 54 years; 55% women), estimating sex differences in prevalence of hypertension (systolic blood pressure ≥130 mm Hg; diastolic blood pressure ≥80 mm Hg; or self-reported antihypertension medication use) and uncontrolled hypertension (systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg) using unadjusted and comorbidity-adjusted models. RESULTS: The prevalence of hypertension increased with age from 40% (ages, 43–46 years) to 93% (ages, 91–94 years). Within hypertensive individuals, the prevalence of uncontrolled hypertension was higher in men (33%) than women (23%) at ages 43 to 46 years but became higher in women than men starting at ages 61 to 64, with 56% of women and 40% men having uncontrolled hypertension at ages 91 to 94. This sex difference was not explained by differences in coronary heart disease, diabetes, body mass index, estimated glomerular filtration rate, number of antihypertension medications, classes of medications, or adherence to medications. In both sexes, uncontrolled hypertension was associated with a higher risk for chronic kidney disease progression (hazard ratio, 1.5 [1.2–1.9]; P=4.5×10−4), heart failure (hazard ratio, 1.6 [1.4–2.0]; P=8.1×10 −7), stroke (hazard ratio, 2.1 [1.6–2.8]; P=1.8×10−8), and mortality (hazard ratio, 1.5 [1.3–1.6]; P=6.2×10−19). CONCLUSIONS: Sex differences in the prevalence of hypertension and uncontrolled hypertension vary by age, with the latter having implications for health throughout the life course. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis

Author

Moledina, Dennis G., Obeid, Wassim, Smith, Rex N., Rosales, Ivy, Sise, Meghan E., Moeckel, Gilbert, Kashgarian, Michael, Kuperman, Michael, Campbell, Kirk N., Lefferts, Sean, Meliambro, Kristin, Bitzer, Markus, Perazella, Mark A., Luciano, Randy L., Pober, Jordan S., Cantley, Lloyd G., Colvin, Robert B., Wilson, F. Perry, and Parikh, Chirag R.

Subjects
Nephritis -- Diagnosis -- Development and progression, Biological markers -- Physiological aspects -- Health aspects -- Identification and classification, Chemokines -- Physiological aspects -- Health aspects -- Identification and classification, Health care industry
Abstract

BACKGROUND. Acute tubulointerstitial nephritis (AIN) is one of the few causes of acute kidney injury with diagnosis- specific treatment options. However, due to the need to obtain a kidney biopsy for histological confirmation, AIN diagnosis can be delayed, missed, or incorrectly assumed. Here, we identify and validate urinary CXCL9, an IFN-[gamma]-induced chemokine involved in lymphocyte chemotaxis, as a diagnostic biomarker for AIN. METHODS. In a prospectively enrolled cohort with pathologist-adjudicated histological diagnoses, termed the discovery cohort, we tested the association of 180 immune proteins measured by an aptamer- based assay with AIN and validated the top protein, CXCL9, using sandwich immunoassay. We externally validated these findings in 2 cohorts with biopsy- confirmed diagnoses, termed the validation cohorts, and examined mRNA expression differences in kidney tissue from patients with AIN and individuals in the control group. RESULTS. In aptamer-based assay, urinary CXCL9 was 7.6-fold higher in patients with AIN than in individuals in the control group (P = 1.23 * [10.sup.-5]). Urinary CXCL9 measured by sandwich immunoassay was associated with AIN in the discovery cohort (n = 204; 15% AIN) independently of currently available clinical tests for AIN (adjusted odds ratio for highest versus lowest quartile: 6.0 [1.8-20]). Similar findings were noted in external validation cohorts, where CXCL9 had an AUC of 0.94 (0.86-1.00) for AIN diagnosis. CXCL9 mRNA expression was 3.9-fold higher in kidney tissue from patients with AIN (n = 19) compared with individuals in the control group (n = 52; P = 5.8 * [10.sup.-6]). CONCLUSION. We identified CXCL9 as a diagnostic biomarker for AIN using aptamer- based urine proteomics, confirmed this association using sandwich immunoassays in discovery and external validation cohorts, and observed higher expression of this protein in kidney biopsies from patients with AIN. FUNDING. This study was supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awards K23DK117065 (DGM), K08DK113281 (KM), R01DK128087 (DGM), R01DK126815 (DGM and LGC), R01DK126477 (KNC), UH3DK114866 (CRP, DGM, and FPW), R01DK130839 (MES), and P30DK079310 (the Yale O'Brien Center). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health., Introduction Sudden loss of kidney function, termed acute kidney injury (AKI), is common, affecting 1 in 5 hospitalized patients and is associated with adverse long-term outcomes, including chronic kidney disease, [...]

Published
2023
Full Text
View/download PDF

34. Cadherin-11, Sparc-related modular calcium binding protein-2, and Pigment epithelium-derived factor are promising non-invasive biomarkers of kidney fibrosis

Author

Knight, Richard, Lecker, Stewart H., Stillman, Isaac, Bogen, Steve, Amodu, Afolarin A., Ilori, Titlayo, Maikhor, Shana, Schmidt, Insa M., Beck, Laurence H., Henderson, Joel M., Onul, Ingrid, Verma, Ashish, McMahon, Gearoid M., Valerius, M. Todd, Waikar, Sushrut, Weins, Astrid, Colona, Mia R., Greka, Anna, Hacohen, Nir, Hoover, Paul J., Marshall, Jamie L., Aulisio, Mark, Chen, Yijiang M., Janowczyk, Andrew, Jayapandian, Catherine, Viswanathan, Vidya S., Bush, William S., Crawford, Dana C., Madabhushi, Anant, Bush, Lakeshia, Cooperman, Leslie, Gonzalez-Vicente, Agustin, Herlitz, Leal, Jolly, Stacey, Nguyen, Jane, O’toole, John, Palmer, Ellen, Poggio, Emilio, Sedor, John, Sendrey, Dianna, Spates-Harden, Kassandra, Taliercio, Jonathan, Bjornstad, Petter M., Pyle, Laura, Vinovskis, Carissa, Appelbaum, Paul, Balderes, Olivia, Barasch, Jonathan M., Bomback, Andrew S., Canetta, Pietro A., D’Agati, Vivette D., Kiryluk, Krzysztof, Kudose, Satoru, Mehl, Karla, Shang, Ning, Bansal, Shweta, Alexandrov, Theodore, Rennke, Helmut, El-Achkar, Tarek M., Barwinska, Daria, Bledso, Sharon, Borner, Katy, Bueckle, Andreas, Cheng, Yinghua, Dagher, Pierre C., Dunn, Kenneth W., Eadon, Michael T., Ferkowicz, Michael J., Herr, Bruce W., Kelly, Katherine J., Ferreira, Ricardo Melo, Quardokus, Ellen M., Record, Elizabeth, Rivera, Marcelino, Su, Jing, Sutton, Timothy A., Williams, James C., Jr., Winfree, Seth, Jain, Yashvardhan, Menez, Steven, Parikh, Chirag R., Rosenberg, Avi, Corona-Villalobos, Celia P., Wen, Yumeng, Johansen, Camille, Rosas, Sylvia E., Roy, Neil, Sun, Jennifer, Williams, Mark, Azeloglu, Evren U., Hansen, Jens, He, Cijang, Iyengar, Ravi, Xiong, Yuguang, Prasad, Pottumarthi, Srivastava, Anand, Madhavan, Sethu M., Parikh, Samir, Rovin, Brad, Shapiro, John P., Anderton, Christopher R., Lukowski, Jessica, Pasa-Tolic, Ljiljana, Velickovic, Dusan, Oliver, George (Holt), Ardayfio, Joseph, Bebiak, Jack, Brown, Keith, Campbell, Taneisha, Campbell, Catherine E., Hayashi, Lynda, Jefferson, Nichole, Roberts, Glenda V., Saul, John, Shpigel, Anna, Stutzke, Christy, Koewler, Robert, Pinkeney, Roy, Sealfon, Rachel, Troyanskaya, Olga, Wong, Aaron, Tuttle, Katherine R., Pollack, Ari, Goltsev, Yury, Ginley, Brandon, Lucarelli, Nicholas, Lutnick, Brendon, Sarder, Pinaki, Lake, Blue B., Zhang, Kun, Boada, Patrick, Laszik, Zoltan G., Nolan, Garry, Anjani, Kavya, Sarwal, Minnie, Mukatash, Tariq, Sigdel, Tara, Alloway, Rita R., Burg, Ashley R., Lee, Paul J., Rike, Adele, Shi, Tiffany, Woodle, E. Steve, Ascani, Heather, Balis, Ulysses G.J., Blanc, Victoria M., Conser, Ninive C., Eddy, Sean, Frey, Renee, He, Yougqun, Hodgin, Jeffrey B., Kretzler, Matthias, Lienczewski, Chrysta, Luo, Jinghui, Mariani, Laura H., Menon, Rajasree, Otto, Edgar, Schaub, Jennifer, Steck, Becky, Elder, Michele M., Gilliam, Matthew, Hall, Daniel E., Murugan, Raghavan, Palevsky, Paul M., Randhawa, Parmjeet, Rosengart, Matthew, Tublin, Mitchell, Vita, Tina, Winters, James, Kellum, John A., Alpers, Charles E., Berglund, Ashley, Berry, Brooke, Blank, Kristina N., Carson, Jonas, Daniel, Stephen, De Boer, Ian H., Dighe, Ashveena L., Dowd, Frederick, Grewenow, Stephanie M., Himmelfarb, Jonathan, Hoofnagle, Andrew N., Limonte, Christine, McClelland, Robyn L., Mooney, Sean D., Rezaei, Kasra, Shankland, Stuart, Snyder, Jamie, Wang, Ruikang, Wilcox, Adam, Williams, Kayleen, Park, Christopher, Montellano, Richard, Pamreddy, Annapurna, Sharma, Kumar, Venkatachalam, Manjeri, Ye, Hongping, Zhang, Guanshi, Basit, Mujeeb, Hedayati, S. Susan, Kermani, Asra, Lee, Simon C., Lu, Christopher Y., Miller, R. Tyler, Moe, Orson W., Patel, Jiten, Pillai, Anil, Sambandam, Kamalanathan, Torrealba, Jose, Toto, Robert D., Vazquez, Miguel, Wang, Nancy, Wen, Natasha, Zhang, Dianbo, Park, Harold, Caprioli, Richard M., Patterson, Nathan, Sharman, Kavya, Spraggins, Jeffrey M., Van de Plas, Raf, Basta, Jeanine, Diettman, Sabine M., Gaut, Joseph P., Jain, Sanjay, Rauchman, Michael I., Vijayan, Anitha, Cantley, Lloyd G., Kakade, Vijaykumar R., Moledina, Dennis, Shaw, Melissa M., Ugwuowo, Ugochukwu, Wilson, Francis P., Arora, Tanima, Kestenbaum, Bryan R., Alexopoulos, Leonidas G., Palsson, Ragnar, Liu, Jing, Stillman, Isaac E., Rennke, Helmut G., Vaidya, Vishal S., Wu, Haojia, Humphreys, Benjamin D., and Waikar, Sushrut S.

Published
2021
Full Text
View/download PDF

36. 24-hour ambulatory blood pressure monitoring 9 years after pediatric cardiac surgery: a pilot and feasibility study

Author

Fredric, Daniel, Greenberg, Jason H., Parikh, Chirag R., Devarajan, Prasad, Chui, Hayton, Cockovski, Vedran, Pizzi, Michael, Palijan, Ana, Hessey, Erin, Jia, Yaqi, Thiessen-Philbrook, Heather R., and Zappitelli, Michael

Subjects
Heart -- Surgery, Children -- Surgery, Blood pressure -- Measurement, Postoperative care -- Methods, Health
Abstract

Background Children undergoing cardiac surgery are at risk of high blood pressure (BP), a risk factor for cardiovascular and kidney disease. Twenty-four-hour ambulatory BP monitoring (ABPM) is a reference standard hypertension (HTN) test. Little data exist on ABPM abnormalities in children several years post cardiac surgery. This study aimed to (a) determine ABPM feasibility; (b) describe and compare ABPM measures and abnormalities (percent load, masked HTN [MH]; non-dipping, mean systolic/diastolic BP > 95th percentile; pre-HTN (ABPM); white-coat HTN [WCH]) to casual BP; and (c) compare BP in patients with and without acute kidney injury (AKI). Methods Prospective, follow-up pilot study of children (0-18 years) who underwent cardiac surgery from 2007 to 2009 at Montreal Children's Hospital. We recorded if participants had post-operative AKI and assessed the following outcomes at 9-year follow-up: casual BP classified by three single-visit measures (normal; elevated BP [eBP.sub.SingleVisit]; HTN.sub.SingleVisit); ABPM. Bivariable analyses were used to compare characteristics between groups. Results Twenty-three patients (median [interquartile range], 8.6 [8.0, 9.0] years post cardiac surgery) were included; 16 (70%) male. Six participants (26%) had eBP.sub.SingleVisit or higher. On ABPM, 11 (48%) had [greater than or equal to] 1 abnormality: 9 (39%) had non-dipping; 3 (13%) had pre-HTN; 3 (13%) had WCH; none had HTN or MH. There were no differences in ABPM according to AKI status. Conclusion Our pilot study determined that ABPM was feasible in children years after cardiac surgery and frequently identified ABPM abnormalities. Future research in larger populations is needed to define specific risk factors for HTN in children after cardiac surgery., Author(s): Daniel Fredric [sup.1] , Jason H. Greenberg [sup.2] , Chirag R. Parikh [sup.3] , Prasad Devarajan [sup.4] , Hayton Chui [sup.1] , Vedran Cockovski [sup.1] , Michael Pizzi [sup.5] [...]

Published
2021
Full Text
View/download PDF

39. A prospective cohort study of acute kidney injury and kidney outcomes, cardiovascular events, and death

Author

Chinchilli, Vernon M., Go, Alan S., Himmelfarb, Jonathan, Ikizler, T. Alp, Kaufman, James S., Kimmel, Paul L., Parikh, Chirag R., Stokes, John B., Coca, Steven, Garg, Amit, Zheng, Sijie, Pravoverov, Leonid, Hsu, Chi-yuan, Hsu, Raymond K., Liu, Kathleen D., Reeves, W. Brian, Siew, Edward D., Lewis, Julia B., Ware, Lorraine, Devarajan, Prasad, Krawczeski, Catherine, Bennett, Michael, Zappitelli, Michael, Wurfel, Mark, Coca, Steven G., Garg, Amit X., Wurfel, Mark M., Ware, Lorraine B., Faulkner, Georgia Brown, and Tan, Thida C.

Published
2021
Full Text
View/download PDF

42. Kidney Transplant Outcomes From Deceased Donors Who Received Dialysis.

Author

Wen, Yumeng, Mansour, Sherry G., Srialluri, Nityasree, Hu, David, Thiessen Philbrook, Heather, Hall, Isaac E., Doshi, Mona D., Mohan, Sumit, Reese, Peter P., and Parikh, Chirag R.

Subjects
KIDNEY transplantation, TREATMENT effectiveness, DEAD, DIALYSIS (Chemistry), HEMODIALYSIS
Abstract

Key Points: Question: Are kidneys from deceased donors who underwent dialysis prior to kidney donation associated with adverse graft outcomes in kidney transplant recipients compared with kidneys from deceased donors who did not undergo dialysis? Findings: In an analysis of 1944 kidney transplant recipients (including 954 who received kidneys from deceased donors who underwent dialysis prior to kidney donation), the incidence of delayed graft function was higher in recipients of kidneys from deceased donors who underwent dialysis prior to kidney donation vs recipients of kidneys from deceased donors who did not undergo dialysis (59.2% vs 24.6%, respectively), but there were no significant differences in the incidence of graft failure (adjusted odds ratio, 0.90) or mortality (adjusted hazard ratio, 0.76) at a median follow-up of 34.1 months. Meaning: Compared with recipients of kidneys from deceased donors who did not undergo dialysis, receiving kidneys from deceased donors who underwent dialysis prior to donation was associated with a higher incidence of delayed graft function, but no difference in graft failure or death at longer-term follow-up. Importance: Recipient outcomes after kidney transplant from deceased donors who received dialysis prior to kidney donation are not well described. Objective: To compare outcomes of transplant recipients who received kidneys from deceased donors who underwent dialysis prior to kidney donation vs recipients of kidneys from deceased donors who did not undergo dialysis. Design, Setting, and Participants: A retrospective cohort study was conducted including data from 58 US organ procurement organizations on deceased kidney donors and kidney transplant recipients. From 2010 to 2018, 805 donors who underwent dialysis prior to kidney donation were identified. The donors who underwent dialysis prior to kidney donation were matched 1:1 with donors who did not undergo dialysis using a rank-based distance matrix algorithm; 1944 kidney transplant recipients were evaluated. Exposure: Kidney transplants from deceased donors who underwent dialysis prior to kidney donation compared with kidney transplants from deceased donors who did not undergo dialysis. Main Outcomes and Measures: The 4 study outcomes were delayed graft function (defined as receipt of dialysis by the kidney recipient ≤1 week after transplant), all-cause graft failure, death-censored graft failure, and death. Results: From 2010 to 2018, 1.4% of deceased kidney donors (805 of 58 155) underwent dialysis prior to kidney donation. Of these 805 individuals, 523 (65%) donated at least 1 kidney. A total of 969 kidneys (60%) were transplanted and 641 kidneys (40%) were discarded. Among the donors with kidneys transplanted, 514 (mean age, 33 years [SD, 10.8 years]; 98 had hypertension [19.1%] and 36 had diabetes [7%]) underwent dialysis prior to donation and were matched with 514 (mean age, 33 years [SD, 10.9 years]; 98 had hypertension [19.1%] and 36 had diabetes [7%]) who did not undergo dialysis. Kidney transplants from donors who received dialysis prior to donation (n = 954 kidney recipients) were associated with a higher risk of delayed graft function compared with kidney transplants from donors who did not receive dialysis (n = 990 kidney recipients) (59.2% vs 24.6%, respectively; adjusted odds ratio, 4.17 [95% CI, 3.28-5.29]). The incidence rates did not significantly differ at a median follow-up of 34.1 months for all-cause graft failure (43.1 kidney transplants per 1000 person-years from donors who received dialysis prior to donation vs 46.9 kidney transplants per 1000 person-years from donors who did not receive dialysis; adjusted hazard ratio [HR], 0.90 [95% CI, 0.70-1.15]), for death-censored graft failure (22.5 vs 20.6 per 1000 person-years, respectively; adjusted HR, 1.18 [95% CI, 0.83-1.69]), or for death (24.6 vs 30.8 per 1000 person-years; adjusted HR, 0.76 [95% CI, 0.55-1.04]). Conclusions and Relevance: Compared with receiving a kidney from a deceased donor who did not undergo dialysis, receiving a kidney from a deceased donor who underwent dialysis prior to kidney donation was associated with a significantly higher incidence of delayed graft function, but no significant difference in graft failure or death at follow-up. This study compares the outcomes of kidney transplant recipients who received kidneys from deceased donors who underwent dialysis prior to kidney donation vs recipients of kidneys from deceased donors who did not undergo dialysis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials.

Author

Zannad, Faiez, Sanyal, Arun J., Butler, Javed, Ferreira, João Pedro, Girerd, Nicolas, Miller, Veronica, Pandey, Ambarish, Parikh, Chirag R., Ratziu, Vlad, Younossi, Zobair M., and Harrison, Stephen A.

Subjects
TYPE 2 diabetes, TRIALS (Law), CHRONIC kidney failure, HEPATOLOGY, REGULATORY approval
Abstract

Steatotic liver disease (SLD) is a worldwide public health problem, causing considerable morbidity and mortality. Patients with SLD are at increased risk for major adverse cardiovascular (CV) events, type 2 diabetes mellitus and chronic kidney disease. Conversely, patients with cardiometabolic conditions have a high prevalence of SLD. In addition to epidemiological evidence linking many of these conditions, there is evidence of shared pathophysiological processes. In December 2022, a unique multi‐stakeholder, multi‐specialty meeting, called MOSAIC (Metabolic multi Organ Science Accelerating Innovation in Clinical Trials) was convened to foster collaboration across metabolic, hepatology, nephrology and CV disorders. One of the goals of the meeting was to consider approaches to drug development that would speed regulatory approval of treatments for multiple disorders by combining liver and cardiorenal endpoints within a single study. Non‐invasive tests, including biomarkers and imaging, are needed in hepatic and cardiorenal trials. They can be used as trial endpoints, to enrich trial populations, to diagnose and risk stratify patients and to assess treatment efficacy and safety. Although they are used in proof of concept and phase 2 trials, they are often not acceptable for regulatory approval of therapies. The challenge is defining the optimal combination of biomarkers, imaging and morbidity/mortality outcomes and ensuring that they are included in future trials while minimizing the burden on patients, trialists and trial sponsors. This paper provides an overview of some of the wide array of CV, liver and kidney measurements that were discussed at the MOSAIC meeting. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Biomarkers of kidney injury among children in a high-risk region for chronic kidney disease of uncertain etiology

Author

Leibler, Jessica H., Ramirez-Rubio, Oriana, Velázquez, Juan José Amador, Pilarte, Damaris López, Obeid, Wassim, Parikh, Chirag R., Gadupudi, Salini, Scammell, Madeleine K., Friedman, David J., and Brooks, Daniel R.

Subjects
Chronic kidney failure -- Risk factors, Teenagers -- Health aspects, Youth -- Health aspects, Occupational health and safety -- Research, Pediatric research, Biological markers -- Research, Health
Abstract

Background Mesoamerican Nephropathy (MeN), a form of chronic kidney disease of uncertain etiology, is a leading cause of death in Central America. The disease often presents in young adult male agricultural workers and progresses rapidly. Given the young age at presentation, we hypothesized that children in Central America experience subclinical kidney injury prior to working life. Methods We assessed specimens from a cross-sectional study of youth, aged 7-17 years, predominantly residing in a high-risk region of Nicaragua (n = 210). We evaluated urinary concentrations and risk factors for kidney injury biomarkers neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), interleukin-18 (IL-18), monocyte chemoattractant protein 1 (MCP-1), and chitinase-3-like protein 1 (YKL-40). We evaluated the association between biomarkers and contemporaneous eGFR and compared biomarker concentrations with reference values from healthy children in other countries. Results Median uNGAL, uIL-18, and uKIM-1 concentrations exceeded healthy reference values. A one-year increase in age was associated with 40% increase in odds of being in the highest quartile of uNGAL (OR 1.4; (95%CI 1.2, 1.5); p < 0.0001). Youth who reported ever experiencing dysuria had 2.5 times the odds of having uNGAL concentrations in the top quartile (OR 2.5; (95%CI 1.4, 4.6); p = 0.003). Girls had significantly higher concentrations of all biomarkers than boys. Nine percent of children demonstrated low eGFR ([less than or equal to] 100 ml/min/1.73 m.sup.2), while 29% showed evidence of hyperfiltration (eGFR [greater than or equal to] 160 ml/min/1.73 m.sup.2), both potentially indicative of renal dysfunction. Conclusions Children residing in regions of Nicaragua at high risk for MeN may experience subclinical kidney injury prior to occupational exposures., Author(s): Jessica H. Leibler [sup.1] , Oriana Ramirez-Rubio [sup.2] [sup.3] , Juan José Amador Velázquez [sup.3] , Damaris López Pilarte [sup.3] , Wassim Obeid [sup.4] , Chirag R. Parikh [sup.4] [...]

Published
2021
Full Text
View/download PDF

47. Contemporary incidence and risk factors of post transplant Erythrocytosis in deceased donor kidney transplantation

Author

Alasfar, Sami, Hall, Isaac E., Mansour, Sherry G., Jia, Yaqi, Thiessen-Philbrook, Heather R., Weng, Francis L., Singh, Pooja, Schröppel, Bernd, Muthukumar, Thangamani, Mohan, Sumit, Malik, Rubab F., Harhay, Meera N., Doshi, Mona D., Akalin, Enver, Bromberg, Jonathan S., Brennan, Daniel C., Reese, Peter P., and Parikh, Chirag R.

Published
2021
Full Text
View/download PDF

50. Beyond kidney dialysis and transplantation: what's on the horizon?

Author

Rabb, Hamid, Lee, Kyungho, and Parikh, Chirag R.

Subjects
Kidneys -- Transplantation, Organs, Culture of -- Research, Chronic kidney failure -- Care and treatment, Microfluidics -- Research, Artificial kidney -- Research, Health care industry
Abstract

There are currently over 750,000 patients with end-stage renal disease (ESRD) in the United States. Globally, 2.6 million patients receive renal replacement therapy with either dialysis or a kidney transplant, [...]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results